Request Demo

Last update 23 Jan 2025

Vascular Headaches

Last update 23 Jan 2025

Basic Info

Synonyms

Cephalgia, Vascular, Cephalgias, Vascular, HEADACHE VASCULAR

+ [23]

Introduction

Secondary headache disorders attributed to a variety of cranial or cervical vascular disorders, such as BRAIN ISCHEMIA; INTRACRANIAL HEMORRHAGES; and CENTRAL NERVOUS SYSTEM VASCULAR MALFORMATIONS.

Drugs associated with Vascular Headaches

Topiramate

Target

AMPA receptor x CAs x GABAA receptor x VGSCs

Mechanism

AMPA receptor antagonists [+3]

Active Org.

Upsher-Smith Laboratories LLC [+8]

Originator Org.

Janssen Global Services LLC

Active Indication

Epilepsy [+6]

Inactive Indication

Affective Disorders, Psychotic [+26]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date24 Dec 1996

TianShu

Target-

Mechanism-

Active Org.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Originator Org.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Active Indication

Vascular Headaches

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1995

Pizotifen

Target

5-HT receptor

Mechanism

5-HT receptor antagonists

Active Org.

Jinan Yongning Pharmaceutical Co. Ltd. [+2]

Originator Org.

Phoenix Labs

Active Indication

Angioedema [+5]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date15 Mar 1974

Clinical Trials associated with Vascular Headaches

NCT04580238

/ WithdrawnPhase 1IIT

Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache

Post stroke headache occurs in approximately 10-23% of all stroke patients. Its onset is shortly after experiencing a stroke, or stroke like event, and persists for at least three months. These headaches have features which resemble migraine or occur in people who have a previous history of migraine that was once infrequent. Botox is a treatment that is currently approved for the treatment of chronic migraine, that is migraine headaches occurring for at least 15 days a month for at least 3 months. Given the clinical similarity in character and frequency of post stroke headache and migraine, and the fact that stroke affects structures like the blood vessels in the brain that are also affected in migraine, this study is to investigate the possible role that Botox would have in the treatment of Post-Stroke Headache.

Start Date01 Dec 2023

Sponsor / Collaborator

University of Alberta

CTR20231424

/ CompletedNot Applicable

盐酸倍他司汀片人体生物等效性研究

[Translation] Study on the bioequivalence of betahistine hydrochloride tablets in healthy volunteers

主要研究目的：研究单次空腹和餐后口服天方药业有限公司生产的盐酸倍他司汀片（8 mg）的药代动力学特征；以Mylan Laboratories SAS生产的盐酸倍他司汀片（Serc®，8 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要研究目的：评估受试制剂（8mg）与参比制剂盐酸倍他司汀片（Serc®，8 mg）在健康受试者的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetic characteristics of betahistine hydrochloride tablets (8 mg) produced by Tianfang Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; using betahistine hydrochloride tablets (Serc®, 8 mg) produced by Mylan Laboratories SAS as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations was evaluated. Secondary purpose of the study: To evaluate the safety of the test preparation (8 mg) and the reference preparation betahistine hydrochloride tablets (Serc®, 8 mg) in healthy subjects.

Start Date09 May 2023

Sponsor / Collaborator

Topfond Pharmaceutical Co. Ltd.

CTR20221065

/ CompletedNot Applicable

健康受试者空腹及餐后状态下口服盐酸倍他司汀片后人体生物等效性试验

[Translation] Bioequivalence study of oral betahistine hydrochloride tablets in healthy subjects in fasting and fed state

主要目的：以济南永宁制药股份有限公司生产，森淼（山东）药业有限公司持有的盐酸倍他司汀片（规格：8mg）为受试制剂，以Mylan Laboratories SAS 公司生产，Mylan Medical SAS 公司销售的盐酸倍他司汀片（商品名：Serc，规格：8mg）为参比制剂，进行空腹/餐后状态下人体生物等效性试验，评价受试制剂与参比制剂的生物等效性。次要目的：观察空腹/餐后状态下，受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: To conduct a human bioequivalence study in the fasting/fed state using Betahistine Hydrochloride Tablets (Specification: 8 mg) produced by Jinan Yongning Pharmaceutical Co., Ltd. and owned by Senmiao (Shandong) Pharmaceutical Co., Ltd. as the test preparation and Betahistine Hydrochloride Tablets (Trade Name: Serc, Specification: 8 mg) produced by Mylan Laboratories SAS and sold by Mylan Medical SAS as the reference preparation, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects in the fasting/fed state.

Start Date07 Jun 2022

Sponsor / Collaborator

Senmiao (Shandong) Pharmaceutical Co., Ltd.

100 Clinical Results associated with Vascular Headaches

100 Translational Medicine associated with Vascular Headaches

0 Patents (Medical) associated with Vascular Headaches

795

Literatures (Medical) associated with Vascular Headaches

01 Jan 2025·Anticancer Research

Vascular Pain and Nurse Burden in Peripheral Administration of Fosaprepitant/Fosnetupitant: A Prospective Observational Study

Article

Author: Sato, Yuko ; Hatakeyama, Shiro ; Kubota, Yuko ; Yoshioka, Takashi ; Ozawa, Chika ; Sawada, Hiroki ; Suzuki, Shuhei

BACKGROUND/AIMVascular pain associated with NK1 receptor antagonists, particularly fosaprepitant, remains a significant challenge in cancer chemotherapy. The present study investigated the incidence of vascular pain with the administration of fosaprepitant and fosnetupitant and assessed the psychological burden on nurses performing venipuncture.PATIENTS AND METHODSWe conducted a prospective observational study involving 115 cancer patients receiving NK1 receptor antagonists via peripheral venous catheters. Vascular pain was evaluated using a numerical rating scale. Nurses' psychological burden was assessed through questionnaires and a qualitative analysis.RESULTSVascular pain occurred in 19% of 304 venipunctures, and its incidence was significantly lower with fosnetupitant (3.1%) than with fosaprepitant (22.9%) (p<0.01). Switching from fosaprepitant to fosnetupitant reduced pain in all cases. Nurses experienced psychological burden in 97% of venipunctures, with severe distress (NRS ≥3) in 19% of cases. The qualitative analysis revealed that nurses' distress was affected by the vascular status, patient behavior, and concerns about drug administration.CONCLUSIONThe incidence of vascular pain was lower with fosnetupitant than with fosaprepitant. Nurses experienced significant psychological burden during venipuncture, particularly when patients reported pain. These results suggest that fosnetupitant is a preferable option for reducing both patient discomfort and nurses' psychological burden in chemotherapy administration.

01 Dec 2024·Alzheimer's & Dementia

Evaluating updated LATE‐NC staging criteria using National Alzheimer’s Coordinating Center data: stage 1 subtypes matter

Article

Author: Corrada, María M. M. ; Head, Elizabeth ; Nguyen, Katelynn M. ; Scambray, Kiana A. ; Sordo, Lorena ; Kawas, Claudia H. ; Nelson, Peter T ; Woodworth, Davis C. ; Sajjadi, S. Ahmad

AbstractBackgroundLimbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic change (LATE‐NC) is a common cause of dementia in older age. LATE‐NC was first coined in 2019 with proposed staging criteria of TDP‐43 progressing from amygdala (stage 1), to hippocampus (stage 2), to middle frontal gyrus (stage 3). Criteria were updated in 2023 to further categorize stage 1 to either TDP‐43 inclusions in amygdala alone (stage 1a) or hippocampus alone (stage 1b). We applied this updated LATE‐NC staging criteria to data from participants in the National Alzheimer’s Coordinating Center (NACC) and examined associations with clinical diagnosis and other neuropathologic changes (NCs).MethodWe selected participants in NACC with regional TDP‐43 assessments, excluding those with frontotemporal dementia‐related and rare NCs, or with a non‐Alzheimer’s disease (AD) etiologic clinical diagnosis. LATE‐NC stages were assigned according to updated criteria. We performed logistic regressions with LATE‐NC stages as predictors and clinical diagnosis (dementia, cognitive impairment, memory impairment), other neuropathologic changes (ADNC, Lewy bodies, hippocampal sclerosis of aging (HS‐A), and vascular NCs), or gross atrophy at autopsy (cortical, hippocampal, frontal/temporal lobar) as outcomes. We also examined the association of LATE‐NC stages with dementia and memory impairment while accounting for other NCs.ResultOf N = 1365 participants, LATE‐NC was present in 519 (37%): 31% stage 1 (78% 1a, 22% 1b), 56% stage 2, 13% stage 3 (Table‐1). Participants with stage 1a were younger at death compared to higher stages. Stage 1a and 1b had similar associations with cognitive problems (Figure‐1). However, while other stages were associated with ADNC and Lewy bodies, stage 1b was not. Meanwhile stage 1b was associated with HS‐A more strongly than stage 1a and to a similar degree as stage 2. We observed expected associations of higher LATE‐NC stages with dementia and other NCs (Figure‐1). Lastly, LATE‐NC stage 1b was significant (and stage 1a trended) for associations with dementia and memory impairment, while higher LATE‐NC stages had associations eclipsed in strength only by highest level ADNC (Figure‐2).ConclusionThese findings highlight the utility of the updated LATE‐NC staging criteria in general, and stage 1 subtypes in particular, in capturing broad associations with cognitive impairment and specific associations with other neuropathologic changes.

01 Nov 2024·Reumatología Clínica (English Edition)

Evaluation of the efficacy and safety of gravitational therapy in a cohort of patients with systemic sclerosis

Article

Author: Isasi, María Eloísa ; Servioli, Luisa Fernanda ; Pérez, Alejandra ; Pouquette, Silvia ; Isasi, Eugenia

BACKGROUNDThe exposure to artificial gravity (AG) through human centrifugation is the basis of the treatment called gravity therapy (GT), in which the mechanical stimulation over the vessel wall, induces the synthesis and release of prostacyclin. It has been used for more than four decades in Uruguay in the treatment of different vascular-based pathologies. In patients with systemic sclerosis (SSc) it has shown good benefits and excellent safety profile over the years. However, there is a lack of knowledge in the scientific community about GT and its results.OBJECTIVETo evaluate the effectiveness of GT in cutaneous and vascular involvement, in the quality of life and functional capacity and its safety profile in patients with SSc.METHODOLOGYIt is a descriptive and retrospective study of patients with SSc assisted in an autoimmunity center in Montevideo, treated with GT in the last 10 years.RESULTSFifty patients were included, 48 women (96%) and 2 men (4%) with a mean age of 62 ± 12 years. The mean time of evolution of SSc at the time of inclusion in the study at the beginning of GT was 6.8 ± 3.2 years and 2.8 ± 3.2 years respectively. After GT, a significant improvement in the modified Rodnan skin score (mRSS) was observed (pre-GT 19.2 ± 8.7 vs. post-GT 5.4 ± 5.0, p < 0.05), which was not related to the time of disease progression at the beginning of GT nor to the skin extension or immunological profile. The degree of improvement post-GT was related to a higher initial mRSS (R = 0.84, p < 0.05). Also, a significant improvement was observed in the number of patients with puffy fingers (pre-GT 50% vs. post-GT 20% patients, p < 0.05), but not in telangiectasias, pitting scars or sclerodactyly. The severity of Raynaud's phenomenon significantly decreased (pre-GT: grade 3-4, 43/48 (89.6%) patients vs. post-GT: grade ≤2, 42/47 (89.4%) patients, p < 0.05) as well as the vascular pain measured with VAS (0-10 scale) (pre-GT: 7.6 ± 2.2 vs. post-TG: 1.4 ± 1.2, p < 0.05). The healing of digital ulcers was also recorded. Regarding the results reported by patients, 97% reported improvement in the quality of life and 89.5% improvement in the ability to carry out activities of daily living. No significant adverse effects were recorded.CONCLUSIONSGT improved cutaneous and vascular involvement, the quality of life and the functional capacity in patients with SSc with an excellent safety profile. Randomized, controlled clinical trials are needed to corroborate these observational results.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vascular Headaches

Basic Info

Related

Analysis